42 results on '"BABUDIERI, S."'
Search Results
2. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C
3. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
4. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
5. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
6. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy
7. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy
8. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life
9. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
10. Natural HCV resistance is common in Italy and differently associated to genotypes
11. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
12. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
13. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
14. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
15. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution
16. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies
17. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment
18. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents
19. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies
20. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment
21. Effectiveness of Simeprevir Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Italian Observational Study
22. Virological Failures to New Direct Acting Antivirals in a Real Life Setting May Require Unconventional Regimens for Re-Treatment
23. P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing
24. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors
25. P1158 EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP EARLY ACCESS PROGRAM
26. P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS
27. P1236 NS3, NS5A AND NS5B COEVOLUTION DURING TREATMENT WITH FIRST-GENERATION PROTEASE INHIBITORS
28. Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey
29. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?
30. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors
31. Proteomic characterization of hepatitis C eradication: Enzyme switch in the healing liver
32. 63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR
33. OC-26 Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the Italian telaprevir early access program
34. OC-27 An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C
35. OC-24 Genotype analysis, at baseline and early time-points, by population and ultra-deep sequencing in HCV patients treated with BOC/TVR-based therapy
36. [567] HCV HEPATITIS AND INTERFERON-RELATED DEPRESSION: AN ANALYSIS OF THE RETROSPECTIVE PHASE OF THE PROBE STUDY
37. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monoteraphy in patients with chronic hepatitis B. A multicenter, randomized trial
38. A young woman with hepatitis after a sore throat
39. Diarrhoea associated with toxigenic Clostridium spiroforme
40. The association between education level and chronic liver disease of any etiology
41. Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done
42. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.